TrialsgrambetaRCTs are beautiful

FLOW

2024

Semaglutide and Kidney Outcomes in Type 2 Diabetes with Chronic Kidney Disease

In 3,533 patients with type 2 diabetes and CKD, semaglutide reduced the composite of kidney failure, ≥50% eGFR decline or renal/CV death compared with placebo.

Result

Efficacy: Kidney failure, ≥50% eGFR decline, or renal or CV deathHR 0.76 (95% CI 0.66-0.88) · P = 0.0003

Below 1 favours semaglutide, above 1 favours placebo.

Also reported: All-cause mortality HR 0.80.

Original publication
Subtopic
GLP-1 RA
Design
Double-blind RCT, stopped early
Relevance
Practice-defining: a trial the guidelines cite as evidence.
Source
Perkovic V, et al. N Engl J Med. 2024;391(2):109-121.doi 10.1056/NEJMoa2403347

Discussion & critique

First GLP-1-agonist trial with a dedicated renal hard endpoint; the benefit was numerically attenuated in the ~16% on background SGLT2 inhibitors.

Discussed in podcasts